Check-Cap Ltd. (CHEK) Files $15.75M IPO

Check-Cap Ltd. (NASDAQ: CHEK) filed with the U.S. SEC for an IPO of its common stock. The proposed maximum offering price is $15.75 million. The ticker "CHEK" was proposed and the company plans to list on the NASDAQ.

Chardan Capital Markets and Maxim Group are lead book-running managers of the offering.

Check-Cap Ltd. is a clinical stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the screening for colorectal cancer, or CRC. While CRC is the second leading cause of death from cancer in the United States and is largely preventable with early detection, about one-half of Americans over the age of 50 do not undergo any form of CRC screening due in large part to the pain, discomfort and embarrassment related to current screening methods. Unlike other structural screening methods that are designed to generate structural information of the colon for the detection of pre-cancerous polyps, such as optical colonoscopy, computed tomographic colonography, or CTC, and other capsule-based technology, the company's imaging capsule is designed to be ingested without any cleansing of the colon and to travel through the gastrointestinal tract naturally while the patient continues his or her normal daily routine. Furthermore, unlike the procedures for CRC imaging devices currently on the market, all of which require the patient to fast for several hours prior to administration, the procedure for the Check-Cap device is designed to enable patients to continue eating normally. The company believes that this solution will be attractive to both physicians and patients, thereby increasing the number of people willing to undergo screening for CRC.

Link to F-1

You May Also Be Interested In

• SpaceX Shares Indicated To Open At $168.75 Each
• AES prices $1 billion senior notes offering with 2029 and 2033 maturities
• Advanced Energy to redeem $136.7 million convertible notes in 2026